Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Psoriasis: full-pipeline trial registry
26 of 127 indexed Psoriasis trials are currently recruiting.
Corpus placement: #93 of 28,707 conditions by registered trial count.
127 US clinical trials · 26 currently recruiting · #93 of 28,707 conditions by registered trial count
Psoriasis: 127 US clinical trials tracked, 26 recruiting.
Psoriasis is the subject of 127 registered US clinical trials on ClinicalTrials.gov, 26 of them currently open to new participants. 50 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 8 of these trials.
Enrollment posture brief
Registry condition psoriasis
OPEN 26 | RECR 20% | LATE 50 | EARLY 36 | RANK #93 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Healthy (21% recruiting · 1,096 trials)
Psoriasis lists 26 open slots (20% of 127 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Psoriasis is recruiting below its size-band peers.
26 of 127 indexed trials (20.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Psoriasis trials is spread across many organizations.
Bristol-Myers Squibb accounts for 8 of 127 trials (6.3%). 65 distinct sponsors appear on at least one study for this condition label.
-
Typical Psoriasis enrolment sits around 84 participants.
Median target enrolment is 84 among the 126 trials that report a genuine target (sentinel values excluded). 68 of those (54%) plan for fewer than 100 participants.
-
Psoriasis research is mostly interventional.
101 interventional and 26 observational studies make up this index (79.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
127 total, page 3 of 3
A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2
Affibody
NCT03580278
A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream
Pyramid Biosciences
NCT05514353
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
Organon and
NCT05789576
Molecular and Cellular Characterization of Spongiotic Dermatitis
University of California, Davis
NCT00371163
Centocor Microarray Study of Patients
University of Rochester
NCT00462072
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Hoffmann-La Roche
NCT00002143
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
Astellas Pharma
NCT00808223
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
University of California, San Francisco
NCT00800982
Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients
Maruho North America
NCT01844973
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
National Heart, Lung, and Blood Institute (NHLBI)
NCT04271735
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
Sun Pharmaceutical Industries
NCT02933528
Evaluating Treatment Resistant Dermatitis TaroIIR
Wake Forest University Health Sciences
NCT03050294
Etanercept With Tacrolimus for Psoriasis
University of Medicine and Dentistry of New Jersey
NCT00134394
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Rockefeller University
NCT00050648
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
Fougera Pharmaceuticals
NCT01137032
Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
Northwestern University
NCT02162472
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
University of North Carolina, Chapel Hill
NCT01320293
An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)
Genentech
NCT00097240
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
Janssen Research & Development
NCT02397382
A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers
Sirtris, a GSK Company
NCT01702493
Immunologic Response to Secukinumab in Plaque Psoriasis
University of California, San Francisco
NCT02592018
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Eli Lilly and Company
NCT02387801
Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy
University of California, Davis
NCT00368654
Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions
Wright State University
NCT04560647
Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
Auritec Pharmaceuticals
NCT03626714
Can We Miss Pigmented Lesions in Psoriasis Patients?
University of Alabama at Birmingham
NCT01053819
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
Glaxo Wellcome
NCT00002286
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 16 |
| Phase 3 | 26 |
| Phase 4 | 24 |
Top Sponsors
Named interventions
Most-linked intervention names on Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Psoriasis page
127 registered trials, 26 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 26 Psoriasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Psoriasis trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Psoriasis condition card totals 127 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.